Quantitative analysis for Nautilus Biotechnology, Inc. (NAUT) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Strong Sell (10.0) (grade F). 27 signals analyzed (23 differentiated alt-data).
NAUT stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $2.68 | $2.43 | $2.50 |
| 2026-05-11 | $3.04 | $2.82 | $3.02 |
| 2026-05-21 | $2.57 | $2.29 | $2.54 |
| 2026-06-03 | $2.72 | $2.58 | $2.58 |
| 2026-06-15 | $2.32 | $2.25 | $2.25 |
| 2026-06-26 | $2.25 | $1.87 | $2.00 |
| 2026-07-09 | $1.95 | $1.83 | $1.90 |
| 2026-07-21 | $1.72 | $1.66 | $1.70 |
| 2026-07-31 | $1.06 | $0.95 | $0.98 |
| 2026-08-12 | $0.92 | $0.88 | $0.90 |
| 2026-08-24 | $0.98 | $0.86 | $0.88 |
| 2026-09-03 | $0.98 | $0.89 | $0.92 |
How Nautilus Biotechnology, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| STRO | Sutro Biopharma, Inc. | $301M | 74.0 |
| BCYC | Bicycle Therapeutics plc | $306M | — |
| STTK | Shattuck Labs, Inc. | $296M | — |
| SLN | Silence Therapeutics plc | $295M | — |
View all Health Care stocks by valuation and signals →
Nautilus Biotechnology, Inc. (NAUT) scores Strong Sell (10.0), and the composite conceals a 70-point disagreement between its dimensions. It is strongest on valuation at 72, and weakest on analyst consensus at 25 and technicals at 2. A stock can carry valuation that high while technicals sits at 2; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| valuation | 72 |
| earnings quality | 51 |
| competitive moat | 27 |
| analyst consensus | 25 |
| technicals | 2 |
StoQuant analyzes 27 signals (23 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Nautilus Biotechnology, Inc. (NAUT): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/NAUT"><img src="https://stoquant.com/badge/NAUT.svg" alt="Nautilus Biotechnology, Inc. (NAUT) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.